ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
ALK inhibitors
ceritinib
inflammatory myofibroblastic tumor
pediatric oncology
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
02
11
2018
revised:
07
01
2019
accepted:
18
01
2019
pubmed:
31
1
2019
medline:
18
12
2019
entrez:
31
1
2019
Statut:
ppublish
Résumé
There is an increasing interest for anaplastic lymphoma kinase (ALK) inhibitors in pediatric oncology for specific entities such as ALK-driven inflammatory myofibroblastic tumor (IMT). IMT treatment can be challenging due to localization of the tumor and in rare cases of metastasis. When standard surgical treatment is not feasible, ALK inhibitors may play an important role, as recently reported for the first-generation ALK inhibitors (crizotinib). However, data on the second-generation ALK inhibitors are limited. We report two emblematic cases of IMT in pediatric patients, treated with the second-generation ALK inhibitor ceritinib in the context of a clinical trial (NCT01742286).
Substances chimiques
Protein Kinase Inhibitors
0
Crizotinib
53AH36668S
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Banques de données
ClinicalTrials.gov
['NCT01742286']
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27645Informations de copyright
© 2019 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.